The safety evaluation of the solid lipid nanoparticles (SLN) which was mainly made of Glyceryl behenate (ATO) had been made to inquiry the possibility that it fitted for intravenous administration.

• 对以山嵛酸甘油酯(ATO，Glyceryl behenate)为主要载体材料的固体脂质纳米粒(SLN，solid lipid nanoparticles)做安全性评价，探讨其作为静脉给药系统的可能性。